Targeted siRNA nanocarrier: a platform technology for cancer treatment

Area of Science:

• Biotechnology
• Nanomedicine
• Molecular Biology

Background:

• Protamine, a small arginine-rich protein, naturally condenses DNA in sperm.
• RNA interference (RNAi) offers therapeutic potential but requires effective delivery systems.
• Targeting specific cancer cell markers is crucial for effective treatment.

Purpose of the Study:

• To utilize protamine's RNA binding capacity for creating targeted therapeutic nanoparticles.
• To develop a modular platform for delivering small interfering RNA (siRNA) against cancer-specific oncogenes.
• To evaluate the efficacy of these nanocarriers in non-small-cell lung cancer (NSCLC) and Ewing sarcoma models.

Main Methods:

• Spontaneous electrostatic assembly of antibody-protamine-siRNA nanoparticles.
• Characterization of nanocarrier architecture using fluorescence microscopy and dynamic light scattering (DLS).
• In vivo studies using NSCLC xenograft models targeting KRAS via EGFR, and Ewing sarcoma models targeting EWS/FLI1.

Main Results:

• Vesicular nanocarrier formation was dependent on antibody-protamine, excess SMCC-protamine, and anionic siRNA.
• Targeted delivery of siRNA using these nanoparticles demonstrated significant efficacy in NSCLC xenografts.
• Ewing sarcoma cell growth was inhibited both in vitro and in vivo by targeting EWS/FLI1 with the nanocarriers.

Conclusions:

• Antibody-protamine-siRNA nanocarriers represent a novel platform technology for targeted cancer therapy.
• This platform enables specific targeting of diverse cell types and previously undruggable targets via RNAi.
• The modular nature of the nanocarriers allows for broad applicability in various cancer types.